Lonza slashes 500 jobs in Switzerland; Patheon inks manufacturing deal;

> CRO Pacific BioLabs has acquired Bay Bioanalytical Laboratory, folding analytical and bioanalytical chemistry into its in vivo preclinical and microbiological testing services. More

> Cytovance Biologics has inked a development and manufacturing deal with Fountain BioPharma for FB301, a novel monoclonal antibody. News

> Patheon ($PTI) has signed on with Pharmalink to manufacture the company's Nefecon treatment for nephropathy, which can lead to renal disease. Article

> Lonza is cutting 500 jobs at its API plant in Switzerland. Story

> Outsourcing-Pharma checked in with a few East Coast-based CMOs, all of which reported only minor damages from last week's hurricane. Report

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.